Prostate Cancer

The company's revenues in the quarter rose to $221.9 million from $161.0 million in Q4 2017, but it missed the consensus Wall Street estimate of $245.3 million.

Company officials said they expect the firm's growth momentum to continue in 2019, with increased penetration both in the US and in European markets.

Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.

The test measures a number of protein biomarkers, including a proprietary antibody, to diagnose prostate cancer and determine its aggressiveness.

As part of the agreement, LifeLabs will serve as an exclusive distributor for MDxHealth's non-invasive liquid biopsy prostate cancer assay In Canada.

The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.

In fiscal Q2, the firm's Diagnostics and Genomics revenues were $39.3 million, up 6 percent year over year from $37.1 million.

The test, for use on the Claros I Analyzer, leverages microfluidic technology in a disposable test cassette to provide results in 10 minutes or less.